Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Discontinued Operations (2022 - 2023)

Historic Cash from Discontinued Operations for Marker Therapeutics (MRKR) over the last 2 years, with Q4 2023 value amounting to -$62938.0.

  • Marker Therapeutics' Cash from Discontinued Operations rose 9714.15% to -$62938.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$6.1 million, marking a year-over-year change of. This contributed to the annual value of -$6.1 million for FY2023, which is 1172.86% down from last year.
  • Marker Therapeutics' Cash from Discontinued Operations amounted to -$62938.0 in Q4 2023, which was up 9714.15% from -$260281.0 recorded in Q3 2023.
  • In the past 5 years, Marker Therapeutics' Cash from Discontinued Operations registered a high of -$62938.0 during Q4 2023, and its lowest value of -$3.0 million during Q2 2023.